TY - JOUR
T1 - Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23
AU - Marques, Diogo F.P.
AU - Kovacs, Dory
AU - Sanchez-Ruiz, Miguel Angel
AU - Rodrigues, Ana Paula
AU - Machado, Ausenda
AU - Mazagatos, Clara
AU - Monge, Susana
AU - Domegan, Lisa
AU - O’Donnell, Joan
AU - Hooiveld, Mariette
AU - Emborg, Hanne Dorthe
AU - Nunes, Baltazar
AU - Carvalho, Carlos
AU - Rose, Angela M.C.
N1 - Funding Information:
This work was conducted as part of the project, \u2018Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza\u2019, funded by the European Centre for Disease Prevention and Control through service contracts with Epiconcept (ECD.12616, ECD.13017, ECD.13350, ECD.14646, and ECD.15029 - implementing framework contract ECDC/2021/016). The support of Epiconcept to the enhancement of laboratory-confirmed SARI surveillance in the Western Balkans was part of the ECDC Accession support activities funded by the European Union. The funder of the study had a role in the protocol development, data interpretation, and the writing of the manuscript, but no role in data collection or analysis. We gratefully acknowledge all the contributors: the country-level SARI surveillance teams that submit data to TESSy regularly, the online workshop participants and the online questionnaire respondents for their invaluable contribution to this evaluation. We also thank our colleagues from Epiconcept (Anthony Nardone, Esther Kissling and Liliana Antunes) and ECDC (Bruno Ciancio) for their contributions to the study protocol development, workshop discussions and manuscript reviews.
Publisher Copyright:
© 2025 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2025/5/22
Y1 - 2025/5/22
N2 - Background: Between 2020 and 2023, ECDC has supported 21 of 30 EU/EEA and six Western Balkan countries by enhancing severe acute respiratory infection (SARI) surveillance to monitor trends, detect unexpected events, evaluate public health interventions, identify risk factors and support vaccine effectiveness studies. Using diverse strategies, countries have implemented SARI surveillance and reported data at national/European levels. Aim: We evaluated European-level SARI surveillance and provided recommendations to achieve objectives and improve key attribute performance. Methods: We analysed 2022/23 surveillance data for completeness. We administered a questionnaire, targeting country-level representatives, to evaluate surveillance attributes (meeting objectives, usefulness, acceptability, timeliness, representativeness) and identify strengths, weaknesses, opportunities and threats. Results: Thirteen countries (13/27) reported data at European level. Data showed good overall completeness but varied across countries and some variables need improvement (vaccination, sequencing). The questionnaire was completed by all 27 countries. Most countries (23/27) reported that the system effectively monitored trends and considered it useful and acceptable (25/27), but only 16 found it timely and 14 representative. Challenges included insufficient case-based data, data linkage issues and insufficient data completeness. Slow/inefficient manual data extraction affected timeliness, while insufficient geographical coverage affected representativeness. Multi-pathogen surveillance was identified as the main strength, heterogeneity of systems the main weakness, improvements of hospital information systems the main opportunity, and lack of sustainable funding the main threat. Conclusions: SARI surveillance was perceived as effective in monitoring trends, useful and acceptable. To achieve additional objectives and enhance timeliness and representativeness, we recommend improving data completeness, digitalisation/automation and geographical coverage.
AB - Background: Between 2020 and 2023, ECDC has supported 21 of 30 EU/EEA and six Western Balkan countries by enhancing severe acute respiratory infection (SARI) surveillance to monitor trends, detect unexpected events, evaluate public health interventions, identify risk factors and support vaccine effectiveness studies. Using diverse strategies, countries have implemented SARI surveillance and reported data at national/European levels. Aim: We evaluated European-level SARI surveillance and provided recommendations to achieve objectives and improve key attribute performance. Methods: We analysed 2022/23 surveillance data for completeness. We administered a questionnaire, targeting country-level representatives, to evaluate surveillance attributes (meeting objectives, usefulness, acceptability, timeliness, representativeness) and identify strengths, weaknesses, opportunities and threats. Results: Thirteen countries (13/27) reported data at European level. Data showed good overall completeness but varied across countries and some variables need improvement (vaccination, sequencing). The questionnaire was completed by all 27 countries. Most countries (23/27) reported that the system effectively monitored trends and considered it useful and acceptable (25/27), but only 16 found it timely and 14 representative. Challenges included insufficient case-based data, data linkage issues and insufficient data completeness. Slow/inefficient manual data extraction affected timeliness, while insufficient geographical coverage affected representativeness. Multi-pathogen surveillance was identified as the main strength, heterogeneity of systems the main weakness, improvements of hospital information systems the main opportunity, and lack of sustainable funding the main threat. Conclusions: SARI surveillance was perceived as effective in monitoring trends, useful and acceptable. To achieve additional objectives and enhance timeliness and representativeness, we recommend improving data completeness, digitalisation/automation and geographical coverage.
UR - https://www.scopus.com/pages/publications/105006415153
U2 - 10.2807/1560-7917.ES.2025.30.20.2400655
DO - 10.2807/1560-7917.ES.2025.30.20.2400655
M3 - Article
C2 - 40406887
AN - SCOPUS:105006415153
SN - 1025-496X
VL - 30
JO - Eurosurveillance
JF - Eurosurveillance
IS - 20
M1 - 2400655
ER -